{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:56:21Z","timestamp":1790571381070,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902334"],"award-info":[{"award-number":["81902334"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ginsenoside Rb2 has demonstrated antitumor activity in multiple malignancies, yet its role in cervical cancer and the underlying mechanism remain unclear. This study investigated the effects of Rb2 on cervical cancer progression and explored whether metabolic reprogramming contributes to PD-L1 regulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell proliferation, migration, invasion, glycolytic activity, lactate production, histone lactylation, and PD-L1 expression were evaluated in cervical cancer cells using CCK-8, EdU, colony formation, wound-healing, Transwell, Seahorse analysis, RT-qPCR, western blotting, flow cytometry, and ChIP-qPCR. LDHA regulation was examined by protein and mRNA stability assays, pharmacological inhibition, lysosome immunoprecipitation, gain- and loss-of-function studies, co-immunoprecipitation, molecular docking, and biotinylated Rb2 pull-down assays. T-cell function was assessed by Jurkat T-cell\u2013tumor cell co-culture and IL-2 ELISA. Xenograft models and clinical samples were used for validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rb2 significantly inhibited cervical cancer cell proliferation, migration, invasion, and xenograft tumor growth, reducing HeLa and SiHa cell viability by approximately 23.4% and 25.7%, respectively. Rb2 selectively downregulated PD-L1 and suppressed glycolysis and lactate production, with reduced H3K18la\/H4K12la lactylation at the PD-L1 promoter. LDHA was the primary glycolytic enzyme reduced by Rb2, without changes in its mRNA. Rb2 decreased LDHA protein stability and promoted its autophagy-lysosome-dependent degradation, with p62 required and the p62\u2013LDHA interaction enhanced by Rb2. Rb2-pretreated tumor cells restored IL-2 production by co-cultured Jurkat T cells, whereas LDHA overexpression reversed this effect. LDHA overexpression partially rescued Rb2\u2019s effects, and LDHA correlated positively with PD-L1 in cervical cancer tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rb2 suppresses cervical cancer progression by promoting p62-dependent autophagic degradation of LDHA, thereby inhibiting glycolysis-associated H3K18la and PD-L1 transcription. These findings reveal a p62\/LDHA\/H3K18la\/PD-L1 signaling axis through which Rb2 exerts its antitumor effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1962784","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:29:25Z","timestamp":1790569765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ginsenoside Rb2 promotes p62-mediated LDHA autophagic degradation to inhibit H3K18la-dependent PD-L1 transcription in cervical cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Xingwei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gynecology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Department of Gynecology, Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Department of Obstetrics and Gynecology, The Affiliated Hospital of Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Department of Gynecology, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Nanjing Women and Children\u2019s Healthcare Hospital, Women\u2019s Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Affiliated Hospital of Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minmin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Department of Gynecology, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(24)00408-2","article-title":"Renewed calls to scale-up cervical cancer screening","volume":"403","author":"Zarocostas","year":"2024","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35334","article-title":"Top advances of the year: Cervical cancer","volume":"130","author":"Duska","year":"2024","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00977-w","article-title":"Treatment advances across the cervical cancer spectrum","volume":"22","author":"Francoeur","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/0118744710247426230925054848","article-title":"The impact of HAPPY (Humanity Assurance Protocol in Interventional Radiotherapy) on the psychological well-being of gynecological cancer patients","volume":"17","author":"Tagliaferri","year":"2024","journal-title":"Curr Radiopharm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1645019","article-title":"HPV infection and the immune microenvironment in cervical cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00468-9","article-title":"Immunotherapy plus chemoradiotherapy in cervical cancer management","volume":"403","author":"Tewari","year":"2024","journal-title":"Lancet (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104673","article-title":"Meta-analysis of clinical trial on the comparative efficacy and safety profiles of immunotherapeutic strategies in cervical cancer","volume":"209","author":"V","year":"2025","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108484","article-title":"PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer","volume":"103","author":"Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.120","article-title":"The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer","volume":"7","author":"Martinez-Cannon","year":"2024","journal-title":"Cancer Drug Resist (Alhambra Calif)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13682","article-title":"Targeting PI3K\u03b1 increases the efficacy of anti-PD-1 antibody in cervical cancer","volume":"170","author":"Jiang","year":"2023","journal-title":"Immunology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-025-02334-4","article-title":"Targeting metabolic-epigenetic-immune axis in cancer: Molecular mechanisms and therapeutic implications","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduction Targeted Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41580-025-00876-7","article-title":"Biochemistry and regulation of histone lysine L-lactylation","volume":"27","author":"Sheng","year":"2026","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2025.8964","article-title":"Histone modifications in cervical cancer: Epigenetic mechanisms, functions and clinical implications (review)","volume":"54","author":"Li","year":"2025","journal-title":"Oncol Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/ijms27020803","article-title":"HPV-driven cervical carcinogenesis: Genetic and epigenetic mechanisms and diagnostic approaches","volume":"27","author":"Legaki","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.62347\/qrtr7828","article-title":"Decoding protein lactylation in the pathogenesis and progression of gynecological cancer","volume":"15","author":"Fang","year":"2025","journal-title":"Am J Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12967-026-07788-w","article-title":"NAT10 and ac4C modification in cancer immunity and metabolism: Emerging mechanisms and therapeutic potential","volume":"24","author":"Yang","year":"2026","journal-title":"J Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.11.007","article-title":"Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics","volume":"87","author":"Sharma","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.07.004","article-title":"'Warburg effect' controls tumor growth, bacterial, viral infections and immunity - Genetic deconstruction and therapeutic perspectives","volume":"86","author":"Pouyss\u00e9gur","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1038\/s41467-018-06841-7","article-title":"Nuclear lactate dehydrogenase A senses ROS to produce \u03b1-hydroxybutyrate for HPV-induced cervical tumor growth","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505762","article-title":"PSMD14-mediated LDHA deubiquitination upregulates ACLY expression via H3K18 lactylation to promote lipid synthesis and pancreatic cancer progression","volume":"12","author":"Lu","year":"2025","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10555-025-10250-w","article-title":"p62\/SQSTM1 in cancer: Phenomena, mechanisms, and regulation in DNA damage repair","volume":"44","author":"Yang","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12967-025-07272-x","article-title":"Lactate at the crossroads of tumor metabolism and immune escape: A new frontier in cancer therapy","volume":"23","author":"Dong","year":"2025","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70014","article-title":"Natural products and cancer: From drug discovery to prevention and therapy","volume":"182","author":"Izzo","year":"2025","journal-title":"Br J Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2174\/0115701646318807240830052736","article-title":"Molecular mechanisms of antiproliferative effects of safranal on cervical cancer: Evidence from bioinformatics analysis","volume":"21","author":"Souandaou Athoumani","year":"2024","journal-title":"Curr Proteomics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116708","article-title":"Natural products as glycolytic inhibitors for cervical cancer treatment: A comprehensive review","volume":"175","author":"Liu","year":"2024","journal-title":"Biomed Pharmacother = Biomed Pharmacotherapie"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.10.011","article-title":"Dietary molecules and experimental evidence of epigenetic influence in cancer chemoprevention: An insight","volume":"83","author":"Ullah","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2018.10.025","article-title":"Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-\u03b2\/Smad signaling","volume":"56","author":"Dai","year":"2019","journal-title":"Phytomed: Int J Phytotherapy Phytopharmacology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.1505.05069","article-title":"Melanin biosynthesis inhibition effects of ginsenoside Rb2 isolated from Panax ginseng berry","volume":"25","author":"Lee","year":"2015","journal-title":"J Microbiol Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189292","article-title":"Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: From mechanisms to therapeutic targets","volume":"1880","author":"Gore","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s43556-025-00275-6","article-title":"Histone and non-histone lactylation: Molecular mechanisms, biological functions, diseases, and therapeutic targets","volume":"6","author":"Peng","year":"2025","journal-title":"Mol BioMed"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-23-0067","article-title":"ESRRB inhibits the TGF\u03b2 signaling pathway to drive cell proliferation in cervical cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41419-025-07923-3","article-title":"NLRP12 decreases TRIM25-mediated HK2 degradation to promote glycolysis and H3K18la in gastric cancer","volume":"16","author":"Zhou","year":"2025","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3390\/ijms20143379","article-title":"Cellular responses to proteasome inhibition: Molecular mechanisms and beyond","volume":"20","author":"Albornoz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Burk","year":"2017","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101671","article-title":"Tumor associated macrophage in HPV(+) tumors: Between immunosuppression and inflammation","volume":"65","author":"Gorvel","year":"2023","journal-title":"Semin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lddd.2025.100188","article-title":"Clinical effects of PD-1 inhibitor camrelizumab in advanced, recurrent, or metastatic cervical cancer: A meta-analysis","volume":"22","author":"Yang","year":"2025","journal-title":"Lett Drug Design Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112615","article-title":"Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications","volume":"28","author":"Zhang","year":"2025","journal-title":"iScience"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.11.006","article-title":"Anticancer natural products targeting immune checkpoint protein network","volume":"86","author":"Chun","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/1061186x.2018.1440400","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy","volume":"27","author":"Li","year":"2019","journal-title":"J Drug Targeting"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.11.007","article-title":"Small molecule-based immunomodulators for cancer therapy","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110634","article-title":"Ginsenosides in cancer: Targeting cell cycle arrest and apoptosis","volume":"382","author":"Shah","year":"2023","journal-title":"Chem Biol Interact"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1962784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:29:26Z","timestamp":1790569766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1962784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":46,"alternative-id":["10.3389\/fonc.2026.1962784"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1962784","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1962784"}}